Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond

Short peptides have great potential as safe and effective anticancer drug leads. Herein, the influence of short cyclic peptides containing the Pro-Pro-Phe-Phe sequence on patient-derived melanoma cells was investigated. Cyclic peptides such as cyclo(Leu-Ile-Ile-Leu-Val-Pro-Pro-Phe-Phe-), called CLA, and cyclo(Pro-homoPro-β3homoPhe-Phe-), called P11, exert the cytotoxic and the cytostatic effects in melanoma cells, respectively. CLA was the most active peptide as it reduced the viability of melanoma cells to 50% of control at about 10 µM, whereas P11 at about 40 µM after 48 h incubation. Interestingly, a linear derivative of P11 did not induce any effect in melanoma cells confirming previous studies showing that cyclic peptides exert better biological activity compared to their linear counterparts. According to in silico predictions, cyclic tetrapeptides show a better pharmacokinetic and toxic profile to humans than CLA. Notably, the spatial structure of those peptides containing synthetic amino acids has not been explored yet. In the Cambridge Structural Database, there is only one such cyclic tetrapeptide, cyclo((R)-β2homoPhe-D-Pro-Lys-Phe-), while in the Protein Data Bank—none. Therefore, we report the first crystal structure of cyclo(Pro-Pro-β3homoPhe-Phe-), denoted as 4B8M, a close analog of P11, which is crucial for drug discovery. Comparative molecular and supramolecular analysis of both structures was performed. The DFT findings revealed that 4B8M is well interpreted in the water solution. The results of complex Hirshfeld surface investigations on the cooperativity of interatomic contacts in terms of electrostatic and energetic features are provided. In short, the enrichment ratio revealed O…H/H…O and C…H/H…C as privileged intercontacts in the crystals in relation to basic and large supramolecular H-bonding synthon patterns. Furthermore, the ability of self-assemble 4B8M leading to a nanotubular structure is also discussed.

[1]  M. Zimecki,et al.  Antiviral Activity of a Cyclic Pro-Pro-β3-HoPhe-Phe Tetrapeptide against HSV-1 and HAdV-5 , 2022, Molecules.

[2]  T. Tuccinardi,et al.  VenomPred: A Machine Learning Based Platform for Molecular Toxicity Predictions , 2022, International journal of molecular sciences.

[3]  G. Spengler,et al.  8-Hydroxyquinoline-Amino Acid Hybrids and Their Half-Sandwich Rh and Ru Complexes: Synthesis, Anticancer Activities, Solution Chemistry and Interaction with Biomolecules , 2021, International journal of molecular sciences.

[4]  K. Parang,et al.  Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold , 2021, Biomolecules.

[5]  J. Bojarska Bio-complexes as supermolecules: towards the design of idealized peptide-based ligands , 2021, Acta Crystallographica Section A: Foundations and Advances.

[6]  J. Bojarska The first supramolecular consideration on crystal of DFMO – promising antiviral and anticancer pan-drug , 2021, Acta Crystallographica Section A: Foundations and Advances.

[7]  P. Zielenkiewicz,et al.  The role of structural biology in pandemic's puzzles: amino acids and short peptides as key players , 2021, Acta Crystallographica Section A: Foundations and Advances.

[8]  M. J. Turner,et al.  CrystalExplorer: a program for Hirshfeld surface analysis, visualization and quantitative analysis of molecular crystals , 2021, Journal of applied crystallography.

[9]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[10]  Hong-Jie Zhang,et al.  Natural Cyclopeptides as Anticancer Agents in the Last 20 Years , 2021, International journal of molecular sciences.

[11]  Wojciech M. Wolf,et al.  Life cycle assessment as tool for realization of sustainable development goals - towards sustainable future of the world: mini review , 2021, Acta Innovations.

[12]  M. Zimecki,et al.  Effects of Modifications on the Immunosuppressive Properties of Cyclolinopeptide A and Its Analogs in Animal Experimental Models , 2021, Molecules.

[13]  G. Borchard,et al.  Short peptide sequence enhances epithelial permeability through interaction with protein kinase C. , 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  P. Naik Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management , 2021, World journal of oncology.

[15]  Siyu Chen,et al.  Nanocarrier-Based Drug Delivery for Melanoma Therapeutics , 2021, International journal of molecular sciences.

[16]  J. Bojarska Short Peptides: On the Trail of Future Stem Cell-Based Regenerative Therapies , 2021, International Journal of Nutritional Sciences.

[17]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[18]  Elham Mousavinezhad Sarasia,et al.  A Global Review on Short Peptides: Frontiers and Perspectives , 2021, Molecules.

[19]  J. Bojarska,et al.  Ultra-Short Cyclo-Peptides as Bio-Inspired Therapeutics: Proline-Based 2,5-Diketopiperazines (DKP) , 2020 .

[20]  M. Czyz,et al.  BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells. , 2020, Cancer letters.

[21]  M. Zimecki,et al.  Anti-Inflammatory Activity of a Cyclic Tetrapeptide in Mouse and Human Experimental Models , 2020, Pharmaceutics.

[22]  Izabela D. Madura,et al.  A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0: A Case Study of ACEI , 2020, Pharmaceuticals.

[23]  J. Moss,et al.  Bacterial Cyclodipeptides Target Signal Pathways Involved in Malignant Melanoma , 2020, Frontiers in Oncology.

[24]  S. Chutipongtanate,et al.  Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review) , 2020, International journal of oncology.

[25]  T. Chua,et al.  The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations. , 2020, Critical reviews in oncology/hematology.

[26]  J. Bojarska,et al.  Synthesis, experimental and in silico studies of N-fluorenylmethoxycarbonyl-O-tert-butyl-N-methyltyrosine, coupled with CSD data: a survey of interactions in the crystal structures of Fmoc-amino acids. , 2020, Acta crystallographica. Section C, Structural chemistry.

[27]  Wojciech M. Wolf,et al.  A Supramolecular Approach to Structure-Based Design with A Focus on Synthons Hierarchy in Ornithine-Derived Ligands: Review, Synthesis, Experimental and in Silico Studies , 2020, Molecules.

[28]  M. Czyz,et al.  Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity , 2020, Cells.

[29]  Peter R. Spackman,et al.  Bridging crystal engineering and drug discovery by utilizing intermolecular interactions and molecular shapes in crystals. , 2019, Angewandte Chemie.

[30]  J. Bojarska,et al.  New synthons in supramolecular chemistry of short biologically active peptides , 2019, Acta Crystallographica Section A: Foundations and Advances.

[31]  J. Bojarska,et al.  Supramolecular synthon polymorphism in modified amino acids. Structural, conformational and energy landscapes of N-benzoyl-2′-hydroxy-3-methylisovaline , 2019, Journal of Molecular Structure.

[32]  P. Hegde,et al.  Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab , 2019, Clinical Cancer Research.

[33]  N. Ditsch,et al.  EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells , 2019, OncoTargets and therapy.

[34]  M. Czyz,et al.  Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program , 2019, Journal of oncology.

[35]  Olivier Michielin,et al.  SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules , 2019, Nucleic Acids Res..

[36]  M. Czyz,et al.  Whole‐exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells , 2019, Molecular carcinogenesis.

[37]  J. Bojarska,et al.  The first insight into the supramolecular structures of popular drug repaglinide: Focus on intermolecular interactions in antidiabetic agents , 2019, Journal of Molecular Structure.

[38]  S. Patel,et al.  Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. , 2018, Cancer epidemiology.

[39]  David S. Goodsell,et al.  RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..

[40]  J. Bojarska,et al.  Supramolecular Chemistry of Modified Amino Acids and Short Peptides , 2018, Advances in Organic Synthesis.

[41]  J. Liaw,et al.  Applications of cyclic peptide nanotubes (cPNTs) , 2018, Journal of food and drug analysis.

[42]  M. A. Abdalla,et al.  Natural Cyclic Peptides as an Attractive Modality for Therapeutics: A Mini Review , 2018, Molecules.

[43]  P. Soares,et al.  Melanoma treatment in review , 2018, ImmunoTargets and therapy.

[44]  G. Mező,et al.  On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site , 2018, Beilstein journal of organic chemistry.

[45]  J. Bojarska,et al.  The experimental and theoretical landscape of a new antiplatelet drug ticagrelor: Insight into supramolecular architecture directed by C-H⋯F, π⋯π and C-H⋯π interactions , 2018 .

[46]  Dmitry S Druzhilovskiy,et al.  CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for drug-like compounds , 2018, PloS one.

[47]  C. Ferrone,et al.  Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. , 2017, Anti-Cancer Agents in Medicinal Chemistry.

[48]  H. Pan,et al.  Antitumour bioactive peptides isolated from marine organisms , 2017, Clinical and experimental pharmacology & physiology.

[49]  Peter R. Spackman,et al.  CrystalExplorer model energies and energy frameworks: extension to metal coordination compounds, organic salts, solvates and open-shell systems , 2017, IUCrJ.

[50]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[51]  M. Czyz,et al.  Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells , 2017, Laboratory Investigation.

[52]  J. Bojarska,et al.  Quantifying intermolecular interactions in solid state indapamide and other popular diuretic drugs: Insights from Hirshfeld surface study , 2016 .

[53]  M. Bar‐eli,et al.  Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection , 2016, Front. Genet..

[54]  Vincent Zoete,et al.  A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules , 2016, ChemMedChem.

[55]  N. Thamwattana,et al.  Modelling water molecules inside cyclic peptide nanotubes , 2016, Applied Nanoscience.

[56]  Girish Kumar Gupta,et al.  Chemical Drug Design , 2016 .

[57]  J. Bojarska,et al.  Investigation of intermolecular interactions in finasteride drug crystals in view of X-ray and Hirshfeld surface analysis , 2015 .

[58]  R. Kefford,et al.  Immune checkpoint inhibitors in melanoma. , 2015, Melanoma management.

[59]  Alexander Tropsha,et al.  Pred‐hERG: A Novel web‐Accessible Computational Tool for Predicting Cardiac Toxicity , 2015, Molecular informatics.

[60]  M. Reaney,et al.  Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment , 2015, Toxicology reports.

[61]  J. Bojarska,et al.  Molecular structure and acidity of captopril, zofenopril and their metabolites captopril disulfide and zofenoprilat , 2015 .

[62]  M. Czyz,et al.  Phenotypic diversity of patient-derived melanoma populations in stem cell medium , 2015, Laboratory Investigation.

[63]  A. Mukherjee Building upon Supramolecular Synthons: Some Aspects of Crystal Engineering , 2015 .

[64]  Leming Sun,et al.  Tunable synthesis of self-assembled cyclic peptide nanotubes and nanoparticles. , 2015, Soft matter.

[65]  J. Bojarska,et al.  Captopril and its dimer captopril disulfide: comparative structural and conformational studies. , 2015, Acta crystallographica. Section C, Structural chemistry.

[66]  M. Ramamoorthy,et al.  In silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases , 2015, Bioinformation.

[67]  G. Sheldrick Crystal structure refinement with SHELXL , 2015, Acta crystallographica. Section C, Structural chemistry.

[68]  J. Bojarska,et al.  Structural and spectroscopic characterization and Hirshfeld surface analysis of major component of antibiotic mupirocin – pseudomonic acid A , 2014 .

[69]  C. Jelsch,et al.  The enrichment ratio of atomic contacts in crystals, an indicator derived from the Hirshfeld surface analysis , 2014, IUCrJ.

[70]  Tjelvar S. G. Olsson,et al.  Evaluation of molecular crystal structures using Full Interaction Maps , 2013 .

[71]  J. Bojarska,et al.  Three new olanzapine structures: the acetic acid monosolvate, and the propan-2-ol and propan-2-one hemisolvate monohydrates. , 2013, Acta crystallographica. Section C, Crystal structure communications.

[72]  Gautam R Desiraju,et al.  Crystal engineering: from molecule to crystal. , 2013, Journal of the American Chemical Society.

[73]  J. Bojarska,et al.  An orthorhombic polymorph of a cyclization product of perindopril. , 2013, Acta crystallographica. Section C, Crystal structure communications.

[74]  J. Bojarska,et al.  Molecular structure of antihypertensive drug perindopril, its active metabolite perindoprilat and impurity F , 2013 .

[75]  J. Bojarska,et al.  CRYSTAL STRUCTURE OF A PERINDOPRIL CYCLIZATION PRODUCT, C19H30N2O4 , 2013 .

[76]  Niall J. Haslam,et al.  Towards the Improved Discovery and Design of Functional Peptides: Common Features of Diverse Classes Permit Generalized Prediction of Bioactivity , 2012, PloS one.

[77]  J. Bojarska,et al.  Novel pseudopolymorph of the active metabolite of perindopril. , 2012, Acta crystallographica. Section C, Crystal structure communications.

[78]  M. Liu,et al.  Self‐Assembling Nanotubes Consisting of Rigid Cyclic γ‐Peptides , 2012 .

[79]  P. Leeson,et al.  Drug discovery: Chemical beauty contest , 2012, Nature.

[80]  S. Joo Cyclic Peptides as Therapeutic Agents and Biochemical Tools , 2012, Biomolecules & therapeutics.

[81]  C. Valéry,et al.  Peptide nanotubes: molecular organisations, self-assembly mechanisms and applications , 2011 .

[82]  J. Bojarska,et al.  Crystal and molecular structure of perindopril erbumine salt , 2011 .

[83]  J. Rundhaug,et al.  Upregulation of the EP1 receptor for prostaglandin E2 promotes skin tumor progression , 2011, Molecular carcinogenesis.

[84]  Z. Wawrzak,et al.  The first crystal structure of a gramicidin complex with sodium: high-resolution study of a nonstoichiometric gramicidin D-NaI complex. , 2010, Acta crystallographica. Section D, Biological crystallography.

[85]  Gautam R. Desiraju,et al.  Long-range synthon Aufbau modules (LSAM) in crystal structures: systematic changes in C6H6−nFn (0 ≤ n ≤ 6) fluorobenzenes , 2010 .

[86]  S. Narumiya,et al.  Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[87]  Richard J. Gildea,et al.  OLEX2: a complete structure solution, refinement and analysis program , 2009 .

[88]  E. Espinosa,et al.  Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. , 2009, European journal of cancer.

[89]  Anthony L. Spek,et al.  Structure validation in chemical crystallography , 2009, Acta crystallographica. Section D, Biological crystallography.

[90]  Dylan Jayatilaka,et al.  Hirshfeld surface analysis , 2009 .

[91]  C. Macrae,et al.  Mercury CSD 2.0 – new features for the visualization and investigation of crystal structures , 2008 .

[92]  E. Poluzzi,et al.  The hERG K+ channel: target and antitarget strategies in drug development. , 2008, Pharmacological research.

[93]  Z. Wawrzak,et al.  Nonstoichiometric complex of gramicidin D with KI at 0.80 A resolution. , 2007, Acta crystallographica. Section D, Biological crystallography.

[94]  E. Baerends,et al.  Kohn-Sham Density Functional Theory: Predicting and Understanding Chemistry , 2007 .

[95]  P. Kongsaeree,et al.  Beta2-amino acids in the design of conformationally homogeneous cyclo-peptide scaffolds. , 2006, The Journal of organic chemistry.

[96]  Matthew P Jacobson,et al.  Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.

[97]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[98]  W. Pangborn,et al.  Structure of gramicidin D-RbCl complex at atomic resolution from low-temperature synchrotron data: interactions of double-stranded gramicidin channel contents and cations with channel wall. , 2005, Acta crystallographica. Section D, Biological crystallography.

[99]  W. Pangborn,et al.  Ion channels in crystals of gramicidin D complex with RbCl. Atomic resolution low-temperature synchrotron X-ray data , 2004 .

[100]  J. G. Snijders,et al.  Accuracy of geometries: influence of basis set, exchange–correlation potential, inclusion of core electrons, and relativistic corrections , 2004 .

[101]  Giovanni Scalmani,et al.  Energies, structures, and electronic properties of molecules in solution with the C‐PCM solvation model , 2003, J. Comput. Chem..

[102]  F. Allen The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[103]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[104]  F. Allen,et al.  Cambridge Structural Database , 2002 .

[105]  I. Muegge,et al.  Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.

[106]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[107]  V. Barone,et al.  Quantum Calculation of Molecular Energies and Energy Gradients in Solution by a Conductor Solvent Model , 1998 .

[108]  Gautam R. Desiraju,et al.  Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis , 1995 .

[109]  A. Becke Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[110]  J. Bernstein,et al.  Graph-set analysis of hydrogen-bond patterns in organic crystals. , 1990, Acta crystallographica. Section B, Structural science.

[111]  H. Kessler,et al.  Conformation of Antamanide , 1989 .

[112]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[113]  L. Curtiss,et al.  Intermolecular interactions from a natural bond orbital, donor-acceptor viewpoint , 1988 .

[114]  John E. Carpenter,et al.  Analysis of the geometry of the hydroxymethyl radical by the “different hybrids for different spins” natural bond orbital procedure , 1988 .

[115]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[116]  Frank Weinhold,et al.  Natural localized molecular orbitals , 1985 .

[117]  F. Weinhold,et al.  Natural population analysis , 1985 .

[118]  Frank Weinhold,et al.  Natural bond orbital analysis of near‐Hartree–Fock water dimer , 1983 .

[119]  F. L. Hirshfeld Bonded-atom fragments for describing molecular charge densities , 1977 .

[120]  D. Cremer,et al.  General definition of ring puckering coordinates , 1975 .

[121]  I. Karle,et al.  Conformations of the li-antamanide complex and na-[phe, val]antamanide complex in the crystalline state. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[122]  J. Bojarska,et al.  Supramolecular Synthons as Related to Cooperativity in Biocomplexes: towards Design and Development of Oligopeptide-Based Modern Drugs and Cosmeceuticals , 2019 .

[123]  R. V. Van Dross,et al.  Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice. , 2016, Prostaglandins, leukotrienes, and essential fatty acids.

[124]  Nicole J. Yang,et al.  Getting across the cell membrane: an overview for small molecules, peptides, and proteins. , 2015, Methods in molecular biology.

[125]  G. Sheldrick A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[126]  T. Wieland,et al.  Conformation of [4-cis-Br-Pro7]-antamanide crystallized from methanol/water , 2004, Naturwissenschaften.

[127]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[128]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[129]  Nicholas C. Handy,et al.  Exchange functionals and potentials , 1996 .

[130]  A. Klamt,et al.  COSMO : a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient , 1993 .

[131]  R. Parr Density-functional theory of atoms and molecules , 1989 .